<DOC>
	<DOCNO>NCT02727309</DOCNO>
	<brief_summary>This study design evaluate efficacy safety TACE combine apatinib treat advanced hepatocellular carcinoma . The primary endpoint progression-free survival ( PFS ) , 3-month PFS , 6-month PFS 1-year PFS .</brief_summary>
	<brief_title>A Study Second-line Treatment With Apatinib After TACE Advanced Hepatocellular Carcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Patients histologic cytologic diagnosis hepatocellular carcinoma Have progress systematic chemotherapy/target therapy , tolerate firstline treatment The previous chemotherapy present trial registration must least 2 week apart . And must recover toxicity previous chemotherapy Patients Child Pugh Class A &amp; B disease eligible study Patients Barcelona Clinic Liver Cancer stage B C eligible study Eastern Cooperative Oncology Group performance score ( PS ) : 02 Life expectancy least 12 week Hepatitis B virus DNA &lt; 2000 IU/ml Adequate organ function meet follow : Bone marrow : absolute neutrophil count ≥1.5×109/L ( 1500/mm3 ) ; platelet ≥ 75×109/L ; hemoglobin ≥9 g/dL Liver : Serum bilirubin ≤ 1.5 ×ULN , AST ALT ≤ 5 ×ULN , ALB ≥ 29 g/L Kidney : Cr ≤1.5 ×upper limit normal Within 7 day prior start therapy , woman childbearing potential must undergo pregnancy test , must negative ; men childbearing potential : contraceptive measure must adopt treatment within 8 week afterward Subjects understand voluntarily sign write informed consent form Previous locoregional therapy within 4 week prior enrollment Diagnosed cholangiocellular carcinoma , mixed cell carcinoma fibrolamellar hepatocellular carcinoma History malignancy within 5 year except nonmelanoma skin cancer , cervix situ carcinoma Prepared liver transplantation Patients contraindication ( active bleeding , ulcer , intestinal perforation , intestinal obstruction , within 30 day major surgery , uncontrolled high blood pressure medication , IIIIV level cardiac insufficiency , severe liver kidney dysfunction ) A previous history Interstitial pulmonary disease , druginduced interstitial disease , radiation pneumonitis require hormonal therapy active interstitial lung disease clinical evidence Use CYP3A4 inhibitor within 7 day CYP3A4 inducer within 12 day prior enrollment Patients central nervous system metastases brain metastasis Previous definite diagnosis neuropsychiatric disturbance , include epilepsy dementia Pregnant lactate woman Patients bone metastasis receive palliative radiation within 4 week prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Apatinib</keyword>
	<keyword>Second-line Treatment</keyword>
	<keyword>Hepatocellular Cancer</keyword>
	<keyword>TACE</keyword>
</DOC>